Older adults who reach their 80s and 90s with the memory performance of people decades younger do not appear to owe that ability to having inherited less Alzheimer's disease risk, according to a study that compared their genetics directly against cognitively typical peers.
Researchers at the Healthy Aging and Alzheimer's Research Care Center at the University of Chicago and the Translational Genomics Research Institute, part of City of Hope, studied 142 SuperAgers and 89 cognitively average older adults recruited from five regional sites in the United States and Canada. Using DNA extracted from blood samples, they examined APOE genotype, the strongest genetic risk factor for Alzheimer's disease, and calculated three separate Alzheimer's polygenic risk scores incorporating thousands of variants.
None of those measures distinguished the two groups. The finding was published in Alzheimer's Research and Therapy.
For families watching a parent or grandparent age, the practical implication is that a genetic test cannot identify who will retain exceptional memory, and a reassuring genetic result does not guarantee it.
The Hypothesis the Study Was Designed to Test
SuperAgers are defined as adults aged 80 and older whose episodic memory performance is at least average for people two to three decades younger. The definition was established in 2008 by Emily Rogalski, who now directs the HAARC Center.
An obvious alternative explanation has hung over nearly two decades of SuperAger research: perhaps these individuals simply drew a favorable genetic hand and inherited very little Alzheimer's risk. Rogalski framed the stakes plainly, noting that if that were true, identifying SuperAgers might be as simple as genetic testing rather than the comprehensive cognitive evaluations currently required.
The team also examined rare genetic variants previously linked to protection or resilience against Alzheimer's disease. Those were not more common among SuperAgers either.
Matt Huentelman of TGen, co-senior author with Rogalski, said the work establishes a boundary for Alzheimer's disease genetics: common risk captured by APOE and current polygenic scores does not explain the SuperAging phenotype. UChicago Medicine also described the findings.
What the Study Established and What It Did Not
This is an observational cohort study establishing an absence, which is a specific and limited kind of finding.
It shows that in this sample, standard genetic risk measures did not separate SuperAgers from typical peers. It does not identify what explains the difference, describe a biological mechanism of resilience, or establish how such resilience develops or whether it can be cultivated.
Some coverage has framed the result as SuperAgers actively resisting genetic risk. That interpretation goes beyond the data. The study found no genetic difference. Concluding that SuperAgers therefore possess an active protective mechanism is a reasonable hypothesis for future work, not a demonstrated finding.
Sample size is a real constraint. With 142 SuperAgers and 89 comparison participants, a modest genetic effect could exist and go undetected. Recruiting people over 80 with exceptional memory is inherently difficult.
The evidence is also not entirely consistent. A separate and much larger analysis published in Alzheimer's and Dementia in January, led by researchers at Vanderbilt University Medical Center and drawing on 18,080 participants across eight national aging cohorts, reported meaningful APOE differences. Compared with cognitively normal adults aged 80 and older, superagers in that analysis were 19% less likely to carry the risk-associated APOE-e4 allele and 28% more likely to carry the protective APOE-e2 allele, as Vanderbilt reported. That study and this one used different cohorts, definitions, and analytic approaches, and reconciling them is unfinished work.
How This Differs from Earlier SuperAger Research
Previous work on this population focused largely on brain structure. Studies have reported that SuperAgers show slower cortical thinning than typical older adults, and postmortem work has described distinctive cellular features and lower accumulation of Alzheimer's-related tangles.
The new genetics paper narrows the field of explanation. If SuperAgers do not differ in inherited risk as currently measured but do differ in brain structure and cognitive outcome, then whatever produces the difference is happening downstream of the genome, in biology, behavior, environment, or some combination.
What Any of This Means for an Ordinary Reader
Very little that is actionable today, and that is worth saying plainly rather than dressing up.
There is no test that identifies future SuperAgers and no intervention shown to produce SuperAger status. Anyone selling a supplement, program, or brain-training product on the strength of SuperAger research is going beyond the evidence.
What is separately well established is that several factors are associated with better cognitive outcomes in later life: treating hearing loss, managing blood pressure and diabetes, maintaining physical activity within your ability, staying socially engaged, treating depression, avoiding smoking, and limiting alcohol. Those recommendations come from a different evidence base and were not tested in this study.
For families, the more immediate question is usually whether a memory change is normal aging or something else. Forgetting a name and recalling it later is common. Changes worth raising with a clinician include repeating questions in the same conversation, difficulty managing finances or medications that were previously handled independently, getting lost in familiar places, or noticeable personality change.
A primary care clinician can perform an initial cognitive assessment and check for reversible contributors including thyroid dysfunction, vitamin B12 deficiency, medication effects, sleep disorders, and depression. Referral to a neurologist or memory clinic follows if warranted.
Adults interested in contributing to this research can ask about enrolling in longitudinal aging studies, which continue recruiting participants across the United States and Canada.
Frequently Asked Questions
Who are SuperAgers? Adults aged 80 and older whose episodic memory performance is at least average for people two to three decades younger, a definition established in 2008.
What did the study find? Neither APOE genotype, three Alzheimer's polygenic risk scores, nor rare protective variants distinguished 142 SuperAgers from 89 cognitively average peers.
Does this mean SuperAgers actively resist genetic risk? The study found no genetic difference. Active resistance is a hypothesis for future work, not something this study demonstrated.
Is the evidence consistent? Not entirely. A much larger analysis of 18,080 participants found superagers less likely to carry APOE-e4 and more likely to carry APOE-e2. The studies used different cohorts and methods.
How big was the study? 142 SuperAgers and 89 comparison participants across five sites in the United States and Canada, a small sample that could miss modest genetic effects.
Can I be tested to see if I will be a SuperAger? No. The study's point is that genetic testing does not identify this group.
When should memory changes be evaluated? Repeating questions in one conversation, new difficulty managing medications or finances, getting lost in familiar places, or personality change all warrant a clinical assessment.
